Plain-English translation of NCT05677490 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a Phase III trial comparing two different chemotherapy regimens for people with advanced, unresectable, or metastatic HER2-negative gastroesophageal adenocarcinoma. One group will receive mFOLFIRINOX (a four-drug chemotherapy combination) plus , while the other group will receive FOLFOX (a three-drug combination) plus . The trial is studying whether adding the extra drug improves how long patients survive and how well the treatment works.
Current treatments for advanced stomach and esophageal cancer have limited success, and doctors want to know if a stronger chemotherapy regimen can help patients live longer and respond better to treatment.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive one of two chemotherapy regimens given intravenously over several months. Throughout the trial, you will have regular imaging scans (CT or MRI) to monitor how your cancer is responding, blood draws to check your health and measure certain markers, and follow-up visits with your cancer team. Your doctor will track how you're feeling and any side effects you experience, and you may be asked to report your symptoms directly using a questionnaire.
AI-generated summary from trial data · Jul 5, 2026 · Not medical advice
United States